enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Nombre de places boursières sur lesquelles les actions de la société sont cotées : 1. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site Web
- engene.com
- Secteur
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Siège Social
- SAINT-LAURENT, Canada
- PDG
- Ronald H. W. Cooper
- Employés
- 81
- Actions en Circulation
- 67.02 M au 2026-09-02
- Flottant
- 32.75 M
- Capitalisation Boursière
- 132.02 M USD
- Initiés
- 0.11%
- Investisseurs Institutionnels
- 84.11%
- Secteur d'Activité (SIC)
- Biological Products, (No Diagnostic Substances)
- FCF
- −104 M USD
- Dette
- 25.2 M USDtrésorerie nette
- Résultats et FCF — pour les 12 mois à 31.07.2026 (dernier rapport de l'entreprise).
Description
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Bourses et Tickers
| Bourse | Ticker | Devise | Prix | Type |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.73 -2.81% | actions ordinaires |
Principaux Actionnaires
| Détenteur | Participation | Actions | Date du Rapport |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 M | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 M | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 M | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 M | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 M | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 M | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 M | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 M | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 M | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 M | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
